Six biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
La Jolla Pharmaceutical Company (LJPC) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, LJPC also gets A’s. For more information, get Portfolio Grader’s complete analysis of LJPC stock.
Incyte Corporation (INCY) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. For more information, get Portfolio Grader’s complete analysis of INCY stock.
Ambit Biosciences Corp. (AMBI) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of AMBI stock.
Progenics Pharmaceuticals, Inc. (PGNX) is seeing ratings go up from a C last week to a B this week. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. For more information, get Portfolio Grader’s complete analysis of PGNX stock.
Celladon Corporation’s (CLDN) ratings are looking better this week, moving up to an A from last week’s B. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of CLDN stock.
This week, Ardelyx, Inc.’s (ARDX) ratings are up from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of ARDX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
